An update on treatments for amyloid heart disease

Br J Cardiol 2013;20:107doi:10.5837/bjc.2013.024 Leave a comment
Click any image to enlarge
Authors:
First published online July 17th 2013

Patients with amyloid heart disease have historically been considered to have a very poor prognosis and were considered almost untreatable. However, recent therapeutic advances are encouraging and likely to have a marked effect on management across the amyloid spectrum. This message needs to be conveyed to cardiologists, not least because there is now benefit to performing an endomyocardial biopsy to determine amyloid type. We provide an update on the significant progress in managing the three most common forms of amyloid heart disease in the UK.

Pay to access this premium content £5

The BJC is introducing a small charge for some of its premium content. On purchase you will receive an email to access the article and have a downloadable PDF to keep. The PDF can be downloaded from a button on the sidebar. Please note the purchase of this article is for your personal use only.
By supporting us in this way, you are helping us to deliver high-quality services to healthcare professionals. We will continue to keep the majority of our content free of charge.


You can access this article without logging in.
But don't miss out on the many Benefits of our Membership. Register Now.
Already a member? Login Now.
THERE ARE CURRENTLY NO COMMENTS FOR THIS ARTICLE - LEAVE A COMMENT